FACTORS ASSOCIATED WITH A BETTER THERAPEUTIC EFFECT OF SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME

ABSTRACT
Aims: To analyze the predictors of therapeutic success after solifenacin treatment. Methods: Between January 2010 and
December 2013, all patients with overactive bladder syndrome (OAB) who consecutively visited the urologic outpatient
clinics at Institute of Kidney Diseases were prospectively enrolled. All enrolled patients received 5mg solifenacin once a
day for 12 weeks. Results: Overall, 648 patients, 332 men, and 316 women, completed the 12-week study. The overall
success rate was 48.8%. The success rate for female patients was superior to that for male patients (55.4% vs. 42.5%,
P < 0.001). The urgency severity scale (USS) score, daytime frequency, nocturia, voided volume, and bladder capacity
were all improved after 12 weeks’ treatment. Multivariate logistic regression analysis revealed that female gender, high
USS score, high maximum flow rate (Qmax), and low post void residual volume (PVR) were all significant predictive
factors for success after antimuscarinic treatment. USS score ¼ 4 and Qmax _ 12 ml/sec were the most strongly predictive
cutoff values for success, with receiver operating characteristic curve (ROC) areas of 0.70 (sensitivity ¼ 66.8%,
specificity ¼ 66.0%) and 0.63 (sensitivity ¼ 80.7%, specificity ¼ 43.1%), respectively. PVR _70 ml was the most predictive
cutoff value for failure, with a ROC area of 0.58 (sensitivity ¼ 18.2%, specificity ¼ 93.7%). Conclusions: Female gender,
high USS score, high Qmax, and low PVR were associated with better therapeutic efficacy. These findings could serve
as an initial guide or assist in consultation regarding the treatment of OAB patients with antimuscarinics.